Breaking News

Recipharm Expands Pharmaceutical Development Capabilities

Invests in oral solid dosage, sterile fill & finish and enhances existing development capabilities.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Recipharm, a CDMO, is expanding its pharmaceutical development capabilities, through investments and the integration of cutting-edge technologies. This investment aims to enhance services for early- and late- stage product development, including clinical study supply at small and pilot scales and wide range of commercial technologies.   Following this investment, services will cover the whole life cycle of a molecule from APIs route scouting to commercial manufacturing of pharmaceutical produc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters